Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia

Summary

HIT is an acquired antibody-mediated disorder strongly associated with thrombosis, including microthrombosis secondary to disseminated intravascular dissemination (DIC). The clinical features of HIT are reviewed from the perspective of the 4Ts scoring system for HIT, which emphasises its characteristic timing of onset of thrombocytopenia. HIT antibodies recognize multimolecular complexes of platelet factor 4 (PF4)/heparin. However, a subset of HIT sera recognise PF4 bound to platelet chondroitin sulfate; these antibodies activate platelets in vitro and in vivo even in the absence of heparin, thus explaining: delayed-onset HIT (where HIT begins or worsens after stopping heparin); persisting HIT (where HIT takes several weeks to recover); spontaneous HIT syndrome (a disorder clinically and serologically resembling HIT but without proximate heparin exposure); and fondaparinux-associated HIT (four distinct syndromes featuring thrombocytopenia that begins or worsens during treatment with fondaparinux), with a new patient case presented with ongoing thrombocytopenia (and fatal haemorrhage) during treatment of HIT with fondaparinux, with fondaparinux-dependent platelet activation induced by patient serum (“fondaparinux cross-reactivity”). Ironically, despite existence of fondaparinux-associated HIT, this pentasaccharide anticoagulant is a frequent treatment for HIT (including one used by the author). HIT can be confused with other disorders, including those with a) timing similar to HIT (e. g. abciximab-associated thrombocytopenia of delayed-onset); b) combined thrombocytopenia/thrombosis (e. g. symmetrical peripheral gangrene secondary to acute DIC and shock liver); and c) both timing of onset and thrombosis (e. g. warfarin-associated venous limb gangrene complicating cancer-associated DIC). By understanding clinical and pathophysiological similarities and differences between HIT and non-HIT mimicking disorders, the clinician is better able to make the correct diagnosis.

Keywords

Heparin-induced thrombocytopenia - platelet activation - thrombosis

• References

• 1 Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost 2011; 09 (Suppl. 01) 105-117.
• 2 Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. Warkentin TE, Greinacher A. eds Heparin-Induced Thrombocytopenia. 2013. 5. Boca Raton, FL: CRC Press; 24-76.
• 3 Warkentin TE, Cuker A. Differential diagnosis of heparin-induced thrombocytopenia and scoring systems. Warkentin TE, Greinacher A. eds Heparin-Induced Thrombocytopenia. 2013. 5. Boca Raton, FL: CRC Press; 77-109.
• 4 Cines DB. et al. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apher 2007; 22: 31-36.
• 5 Hill M. Secretion of heparin by mast cells. Nature 1957; 180: 654-655.
• 6 Jordan RE. et al. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980; 255: 10081-10090.
• 7 Weitz JI. Heparan sulfate: antithrombotic or not?. J Clin Invest 2003; 111: 952-954.
• 8 Amiral J. et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-96.
• 9 Kelton JG. et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 3232-3239.
• 10 Greinacher A. et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterisation of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71: 247-251.
• 11 Visentin GP. et al. Antibodies from patients with heparin-induced thrombocy-topenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-88.
• 12 Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocy-topenia. N Engl J Med 2001; 344: 1286-1292.
• 13 Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2015; 373: 252-262.
• 14 Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 02: 148-157.
• 15 Lo GK. et al. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 04: 759-765.
• 16 Cuker A. et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012; 120: 4160-4167.
• 17 Warkentin TE, Linkins LA. Non-necrotizing heparin-induced skin lesions and the 4T’s score. J Thromb Haemost 2010; 08: 1483-1485.
• 18 Linkins LA. et al. Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood 2015; 126: 597-603.
• 19 Warkentin TE. et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
• 20 Warkentin TE. et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163: 2518-2524.
• 21 Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121: 535-555.
• 22 Greinacher A, Warkentin TE. Acquired non-immune thrombocytopenia. Marder VJ, Aird WC, Bennett JS, Schulman S, White GC. eds Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 2013. 6. Philadelphia: Lippincott Williams & Wilkins; 796-804.
• 23 Kelton JG, Sheridan D, Santos A. et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925-930.
• 24 Warkentin TE. Drug-induced immune-mediated thrombocytopenia-from purpura to thrombosis. N Engl J Med 2007; 356: 891-893.
• 25 Warkentin TE. Agents for the treatment of heparin-induced thrombocytopenia. Hematol/Oncol Clin N Am 2010; 24: 755-775 ix.
• 26 Warkentin TE. Heparin-induced skin lesions. Br J Haematol 1996; 92: 494-497.
• 27 Greinacher A. et al. The temporal profile of the anti-PF4/heparin immune response. Blood 2009; 113: 4970-4976.
• 28 Warkentin TE. et al. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009; 113: 4963-4969.
• 29 Warkentin TE. et al. Heparin-induced thrombocytopenia in medical surgical critical illness. Chest 2013; 144: 848-858.
• 30 Lubenow N. et al. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 2002; 122: 37-42.
• 31 Warkentin TE, Sheppard JI. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood 2014; 123: 2485-2493.
• 32 Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135: 502-506.
• 33 Warkentin TE. ischaemic limb gangrene with pulses. N Engl J Med 2015; 373: 642-655.
• 34 Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101: 502-507.
• 35 Warkentin TE. HITlights: a career perspective on heparin-induced thrombocytopenia. Am J Hematol 2012; 87 (Suppl. 01) S92-S99.
• 36 Warkentin TE. History of heparin-induced thrombocytopenia. Warkentin TE, Greinacher A. eds Heparin-Induced Thrombocytopenia. 2013. 5. Boca Raton, FL: CRC Press; 1-23.
• 37 Hong AP. et al. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003; 101: 3049-3051.
• 38 Warkentin TE. et al. Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages. N Engl J Med 2015; 372: 492-494.
• 39 Fesler MJ. et al. Heparin-induced thrombocytopenia and cerebral venous sinus thrombosis: case report and literature review. Neurocrit Care 2011; 15: 161-165.
• 40 Warkentin TE. et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127: 804-812.
• 41 Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Semin Thromb Hemost 2015; 41: 49-60.
• 42 Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf 2009; 08: 129-144.
• 43 Warkentin TE. et al. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med 1994; 97: 489-491.
• 44 Hillis C. et al. Chills and limb pain following administration of low-molecular-weight heparin for treatment of acute venous thromboembolism. Am J Hematol 2011; 86: 603-606.
• 45 Tassava T, Warkentin TE. Non-injection site necrotic skin lesions complicating postoperative heparin thromboprophylaxis. Am J Hematol 2015; 90: 747-750.
• 46 Cuker A. et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010; 08: 2642-2650.
• 47 Warkentin TE, Anderson JAM. How I treat patients with a history of heparin-induced thrombocytopenia. Blood 2016; 128: 348-359.
• 48 Padmanabhan A. et al. Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis. Blood 2015; 125: 155-161.
• 49 Refaai MA. et al. Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: a consequence of heparin “flushes”. Thromb Haemost 2007; 98: 1139-1140.
• 50 Kopolovic I, Warkentin TE. Progressive thrombocytopenia after cardiac surgery in a 67-year-old man. CMAJ 2014; 186: 929-933.
• 51 Warkentin TE. et al. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008; 121: 632-636.
• 52 Jay RM, Warkentin TE. Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of ‘spontaneous’ HIT?. J Thromb Haemost 2008; 06: 1598-1600.
• 53 Pruthi RK. et al. Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery ‘spontaneous’ HIT?. J Thromb Haemost 2009; 07: 499-501.
• 54 Warkentin TE. et al. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. Blood 2014; 123: 3651-3654.
• 55 Greinacher A. Me or not me? The danger of spontaneity. Blood 2014; 123: 3536-3538.
• 56 Mallik A. et al. A patient with ‘spontaneous’ heparin-induced thrombocytopenia and thrombosis after undergoing knee replacement. Blood Coagul Fibrinolysis 2011; 22: 73-75.
• 57 Ketha S. et al. Adrenal hemorrhage due to heparin-induced thrombocytopenia. Thromb Haemost 2013; 109: 669-675.
• 58 Bito S. et al. Mechanical prophylaxis is a heparin-independent risk for anti-platelet factor 4/heparin antibody formation after orthopedic surgery. Blood 2016; 127: 1036-1043.
• 59 Olah Z. et al. Rapid-onset heparin-induced thrombocytopenia without previous heparin exposure. Platelets 2012; 23: 495-498.
• 60 Perrin J. et al. Rapid onset heparin-induced thrombocytopenia (HIT) without history of heparin exposure: a new case of so-called ‘spontaneous’ HIT. Thromb Haemost 2012; 107: 795-797.
• 61 Okata T. et al. Spontaneous heparin-induced thrombocytopenia syndrome without any proximate heparin exposure, infection, or inflammatory condition: atypical clinical features with heparin-dependent platelet activating antibodies. Platelets 2015; 26: 602-607.
• 62 Warkentin TE. et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106: 3791-3796.
• 63 Warkentin TE. et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 2011; 140: 366-373.
• 64 Schindewolf M. et al. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT) - findings from the GerHIT multi-centre registry study. Thromb Res 2014; 134: 29-35.
• 65 Warkentin TE. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program 2011; 2011: 143-149.
• 66 Warkentin TE. et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost 2011; 09: 2389-2396.
• 67 Kang M. et al. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood 2015; 125: 924-929.
• 68 Snodgrass MN. et al. Efficacy and safety of fondaparinux in patients with suspected heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2016 Epub ahead of print.
• 69 Warkentin TE. Fondaparinux: does it cause HIT? can it treat HIT?. Exp Rev He-matol 2010; 03: 567-581.
• 70 Warkentin TE. et al. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-2654.
• 71 Warkentin TE. et al. The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome. Thromb Haemost 2012; 108: 394-396.
• 72 Warkentin TE. et al. HIT complicating fondaparinux prophylaxis: fondaparinux-dependent platelet activation as a marker for fondaparinux-induced HIT. Thromb Haemost 2014; 112: 1319-1322.
• 73 Linkins LA, Warkentin TE. Heparin-induced thrombocytopenia: real world issues. Semin Thromb Hemost 2011; 37: 653-663.
• 74 Tvito A. et al. Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment. Am J Hematol 2015; 90: 675-678.
• 75 Alsaleh KA. et al. Delayed-onset heparin-induced thrombocytopenia caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis. Am J Hematol 2008; 83: 876-878.
• 76 Warkentin TE, Lim W. Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal. J Thromb Haemost 2008; 06: 1243-1246.
• 77 Rota E. et al. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008; 99: 779-781.
• 78 Warkentin TE. Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Exp Opin Drug Saf 2014; 13: 25-43.
• 79 Lubenow N. et al. Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia. Report of four cases and review of literature. Thromb Res 2000; 100: 115-125.
• 80 Shtairid M. et al. Post-transfusion purpura: a challenging diagnosis. Isr Med Assoc J 2006; 08: 672-674.
• 81 Hron G. et al. Alternative diagnosis to heparin-induced thrombocytopenia in two critically ill patients despite a positive PF4/heparin-antibody test. Ups J Med Sci 2013; 118: 279-284.
• 82 Berkowitz SD. et al. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997; 95: 809-813.
• 83 Curtis BR. et al. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004; 02: 985-992.
• 84 Siegal DM. et al. Acute hepatic necrosis and ischaemic limb necrosis. N Engl J Med 2012; 367: 879-881.
• 85 Warkentin TE. ischaemic limb gangrene with pulses (correspondence). N Engl J Med 2015; 373: 2386-2388.
• 86 Warkentin TE. et al. Warfarin-induced venous limb ischaemia/gangrene complicating cancer: a novel and clinically distinct syndrome. Blood 2015; 126: 486-493.
• 87 Warkentin TE. Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis. Ann Intern Med 2001; 135: 589-593.
• 88 Warkentin TE. Pseudo-heparin-induced thrombocytopenia. Warkentin TE, Greinacher A. eds Heparin-Induced Thrombocytopenia. 2007. 4. New York: Informa Healthcare USA, Inc; 261-282.